Challenges to the establishment of a monitoring method for the anticoagulant effect of anti-factor Xa inhibitor

被引：0
|
作者：
Nagae, Chiai [1 ]
Ashikaga, Tomoko [1 ,2 ]
Akita, Mieko [1 ]
Yamazaki, Satoshi [3 ]
Takayama, Shigenobu [4 ]
Tatsunami, Shinobu [5 ]
Taki, Masashi [2 ]
机构：
[1] St Marianna Univ, Sch Med, Dept Pediat, Kawasaki, Kanagawa, Japan
[2] Yokohama City Seibu Hosp, Yokohama, Kanagawa, Japan
[3] St Marianna Univ, Dept Clin Lab, Sch Med Hosp, Kawasaki, Kanagawa, Japan
[4] Daito Bunka Univ, Fac Hlth Sci, Tokyo, Japan
[5] St Marianna Univ, Dept Med Stat, Sch Med, Kawasaki, Kanagawa, Japan
来源：
HAEMOPHILIA | 2014年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：52 / 52
页数：1
相关论文
共 50 条
  • [21] Idraparinux sodium - Anticoagulant - Factor Xa inhibitor
    Diaz-Ricart, M
    del Fresno, M
    DRUGS OF THE FUTURE, 2002, 27 (07) : 639 - 644
  • [22] Anti-Factor Xa Monitoring of Enoxaparin Thromboembolism Prophylaxis in Emergency General Surgery Patients
    Pokrzywa, Courtney J.
    Biesboer, Elise A.
    Figueroa, Juan
    Al Tannir, Abdul Hafiz
    de Moya, Marc
    Morris, Rachel S.
    Murphy, Patrick B.
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2023, 237 (02) : 195 - 203
  • [23] Anti-factor Xa monitoring of anticoagulation during cardiopulmonary bypass in a patient with antiphospholipid syndrome
    Lennon, MJ
    Thackray, NM
    Gibbs, NM
    ANAESTHESIA AND INTENSIVE CARE, 2003, 31 (01) : 95 - 98
  • [24] ANTI-FACTOR XA MONITORING OF HEPARIN FOR THE TREATMENT OF PULMONARY EMBOLISM MANAGED BY A PERT TEAM
    Zhu, Eric
    Yuriditsky, Eugene
    Raco, Veronica
    Katz, Alyson
    Papadopoulos, John
    Pashun, Raymond
    Horowitz, James
    Ahuja, Tania
    CRITICAL CARE MEDICINE, 2024, 52
  • [25] The distribution of anti-factor Xa activity value, PT and APTT at peak and trough times in patients with direct anti-factor Xa inhibitors
    Ono, R.
    Fukushima, K.
    Yamazaki, T.
    Takahashi, H.
    Hori, Y.
    EUROPEAN HEART JOURNAL, 2020, 41 : 3368 - 3368
  • [26] Comparing Anti-Factor Xa and Activated Partial Thromboplastin Levels for Monitoring Unfractionated Heparin
    Wahking, Rebekah A.
    Hargreaves, Rachel H.
    Lockwood, Sean M.
    Haskell, Sabrina K.
    Davis, Kelly W.
    ANNALS OF PHARMACOTHERAPY, 2019, 53 (08) : 801 - 805
  • [27] Effects of four commercially available factor Xa proteins on the fluorogenic anti-factor Xa assay when monitoring unfractionated heparin
    Castro-Lopez, Vanessa
    Murray, Brian
    Harris, Leanne F.
    O'Donnell, James S.
    Killard, Anthony J.
    BLOOD COAGULATION & FIBRINOLYSIS, 2012, 23 (01) : 98 - 103
  • [28] IDIOPATHIC CIRCULATING ANTI-FACTOR VIII ANTICOAGULANT
    CORBUS, HF
    CALIFORNIA MEDICINE, 1963, 99 (05): : 335 - &
  • [29] Study of two techniques for heparin therapy monitoring with an amidolytic anti-factor Xa assay
    Rosborough, TK
    Wolfson, PA
    LABORATORY MEDICINE, 2002, 33 (10) : 789 - 790
  • [30] ANTI-FACTOR XA VERSUS ACTIVATED PARTIAL THROMBOPLASTIN TIME FOR HEPARIN INFUSION MONITORING
    Jung, Sul
    Choi, Austin
    Lepore, Mark
    CRITICAL CARE MEDICINE, 2020, 48
12345